Us Bancorp \De\ Avadel Pharmaceuticals PLC Transaction History

Us Bancorp \De\

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$12.55 - $17.22 $439 - $602	-35 Reduced 0.19%	18,447 $311,000
Q4 2023 Feb 09, 2024	BUY	$9.64 - $14.59 $1,571 - $2,378	163 Added 0.89%	18,482 $260,000
Q3 2023 Nov 03, 2023	BUY	$10.3 - $15.99 $710 - $1,103	69 Added 0.38%	18,319 $188,000
Q4 2022 Feb 13, 2023	BUY	$5.02 - $10.0 $81,524 - $162,400	16,240 Added 807.96%	18,250 $130,000
Q3 2022 Oct 27, 2022	BUY	$2.57 - $7.31 $5,165 - $14,693	2,010 New	2,010 $10,000
Q1 2022 May 11, 2022	SELL	$5.46 - $8.29 $1,774 - $2,694	-325 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$7.34 - $11.18 $2,385 - $3,633	325 New	325 $3,000
Q4 2019 Feb 04, 2020	SELL	$3.34 - $7.7 $1,215 - $2,802	-364 Closed	0 $0
Q3 2019 Nov 08, 2019	BUY	$1.92 - $4.47 $698 - $1,627	364 New	364 $1,000
Q2 2019 Aug 13, 2019	SELL	$1.09 - $3.19 $13,625 - $39,875	-12,500 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$8.35 - $10.5 $104,375 - $131,250	12,500	12,500 $131,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.